Effects of SGLT2 inhibitors on clinical cancer survival in patients with type 2 diabetes
Main finding · Cancer-specific mortalityResult — go to the resultAdjusted hazard ratio 0.21 95 % CI 0.20–0.22Authors' conclusion
SGLT2is increase overall survival and cancer-specific survival in patients with cancer in a dose-dependent manner.
Study context
- Population
- Patients with T2D diagnosed with cancer between January 1, 2016, and December 31, 2018, undergoing standard curative treatments, Taiwan Cancer Registrymatched cohort
- Participants
- 50,133 patients
- Exposure
- SGLT2i users vs nonusers
- SGLT2i usersn = 16,711
- Nonusersn = 33,422reference
- Outcome
- Cancer-specific mortality
Methodological details1:2 propensity score matched, Taiwan Cancer Registry database
- 1:2 propensity score matched
- Taiwan Cancer Registry database
Main finding
As reported in the abstract
Adjusted hazard ratio
0.21
95 % CI 0.20–0.22
SGLT2i usersvs Nonusers
aHR 0.21 (95 % CI 0.20–0.22)
Observational data: associations, not effects.
Secondary outcomes
| Outcome | aHR (95 % CI) | |
|---|---|---|
| All-cause mortality | 0.22 (0.21–0.23) | |
| 0.20.5125Adjusted hazard ratio (log scale) |
| Outcome | P value |
|---|---|
| All-cause and cancer-specific mortality by quartiles of cDDDsMortality decreased with increasing dosage from Q1 to Q4 | P < 0.001 |
All-cause and cancer-specific mortality by quartiles of cDDDs
- All-cause and cancer-specific mortality significantly decreased with increasing dose (Q1 to Q4 cDDDs) in SGLT2i users vs nonusers
Original publication
Effects of SGLT2 inhibitors on clinical cancer survival in patients with type 2 diabetes. Diabetes Metab. Published 28 November 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →